Silencing of the STAT3 signaling pathway reverses the inherent and induced chemoresistance of human ovarian cancer cells

Biochemical and Biophysical Research Communications

Volumn 435, Issue 2, 2013, Pages 188-194

  Han, Zhiqiang ^a   Feng, Jing ^a   Hong, Zhenya ^a   Chen, Lijuan ^a   Li, Wei ^a   Liao, Shujie ^a   Wang, Xiaoli ^a   Ji, Teng ^a   Wang, Shixuan ^a   Ma, Ding ^a   Chen, Gang ^a   Gao, Qinglei ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Chemoresistance; Ovarian cancer; Signaling pathway; STAT3

Indexed keywords

CISPLATIN; CYTOCHROME C; INTERLEUKIN 6; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; SMALL INTERFERING RNA; STAT3 PROTEIN;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER RESISTANCE; CELL PROTECTION; CELL SURVIVAL; CHEMOSENSITIVITY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE SILENCING; HUMAN; HUMAN CELL; MITOCHONDRIAL MEMBRANE POTENTIAL; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE SILENCING; HUMANS; OVARIAN NEOPLASMS; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR;

EID: 84878432699     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2013.04.087     Document Type: Article

References (33)

1. Bast R.C. Molecular approaches to personalizing management of ovarian cancer. Ann. Oncol. 2011, 22(Suppl. 8):85-815.
2. Yu H., Jove R. The STATs of cancer: new molecular targets come of age. Nat. Rev. Cancer 2004, 4:97-105.
3. Meinhold-Heerlein I., Bauerschlag D., Hilpert F., et al. Molecular and prognostic distinction between serous ovarian carcinomas of varying grade and malignant potential. Oncogene 2005, 24:1053-1065.
4. Duan Z., Foster R., Bell D.A., et al. Signal transducers and activators of transcription 3 pathway activation in drugresistant ovarian cancer. Clin. Cancer Res. 2006, 12:5055-5063.
5. Rosen D.G., Mercado-Uribe I., Yang G., et al. The role of constitutively active signal transducer and activator of transcription 3 in ovarian tumorigenesis and prognosis. Cancer 2006, 107:2730-2740.
6. Guo Y., Xu F., Lu T., et al. Interleukin-6 signaling pathway in targeted therapy for cancer. Cancer Treat. Rev. 2012, 38:904-910.
7. George J.A., Chen T., Taylor C.C. SRC tyrosine kinase and multidrug resistance protein-1inhibitions act independently but cooperatively to restore paclitaxel sensitivity to paclitaxel-resistant ovarian cancer cells. Cancer Res. 2005, 65:10381-10388.
8. Lee S., Choi E.J., Jin C., et al. Activation of PI3K/Akt pathway by PTEN reduction and PIK3CA mRNA amplification contributes to cisplatin resistance in an ovarian cancer cell line. Gynecol. Oncol. 2005, 97:26-34.
9. Barré B., Vigneron A., Perkins N., et al. The STAT3 oncogene as a predictive marker of drug resistance. Trends Mol. Med. 2007, 13:4-11.
10. Han Z., Hong Z., Chen C., et al. A novel oncolytic adenovirus selectively silences the expression of tumor-associated STAT3 and exhibits potent antitumoral activity. Carcinogenesis 2009, 30:2014-2022.
11. Zhou W., Grandis J.R., Wells A. STAT3 is required but not sufficient for EGF receptor-mediated migration and invasion of human prostate carcinoma cell lines. Br. J. Cancer 2006, 95:164-171.
12. -δδCT method. Methods 2001, 25:402-408.
13. Yan X., Fraser M., Qiu Q., et al. Overexpression of PTEN sensitizes human ovarian cancer cells to cisplatin-induced apoptosis in a p53-dependent manner. Gynecol. Oncol. 2006, 102:348-355.
14. Hong Z., Xiao M., Yang Y., et al. Arsenic disulfide synergizes with the phosphoinositide 3-kinase inhibitor PI-103 to eradicate acute myeloid leukemia stem cells by inducing differentiation. Carcinogenesis 2011, 32:1550-1558.
15. Carlo-Stella C., Di Nicola M., Turco M.C., et al. The anti-human leukocyte antigen-DR monoclonal antibody 1D09C3 activates the mitochondrial cell death pathway and exerts a potent antitumor activity in lymphoma-bearing nonobese diabetic/severe combined immunodeficient mice. Cancer Res. 2006, 66:1799-1808.
16. Chazotte B. Labeling mitochondria with TMRM or TMRE. Cold Spring Harb. Protoc. 2011, 2011:895-897.
17. Guo J.P., Shu S.K., He L., et al. Deregulation of IKBKE is associated with tumor progression, poor prognosis, and cisplatin resistance in ovarian cancer. Am. J. Pathol. 2009, 175:324-333.
18. Lee M.H., Kim S.J., Park S.N. Development of porous cellulose-hydrogel system for enhanced transdermal delivery of quercetin and rutin. Korea Polym. J. 2013, 37(3):347-355.
19. Nolen B., Marrangoni A., Velikokhatnaya L., et al. A serum based analysis of ovarian epithelial tumorigenesis. Gynecol. Oncol. 2009, 112:47-54.
20. Moradi M.M., Carson L.F., Weinberg B., et al. Serum and ascitic fluid levels of interleukin-1, interleukin-6, and tumor necrosis factor-alpha in patients with ovarian epithelia cancer. Cancer 1993, 72:2433-2440.
21. Penson R.T., Kronish K., Duan Z., et al. Cytokines IL-1beta, IL-2, IL-6, IL-8, MCP-1, GM-CSF and TNFalpha in patients with epithelial ovarian cancer and their relationship to treatment with paclitaxel. Int. J. Gynecol. Cancer 2000, 10:33-41.
22. Li S., Wang N., Brodt P. Metastatic cells can escape the proapoptotic effects of TNF-α through increased autocrine IL-6/STAT3 signaling. Cancer Res. 2012, 72:865-875.
23. Griguer C.E., Oliv C.R. Bioenergetics pathways and therapeutic resistance in gliomas: emerging role of mitochondria. Curr. Pharm. Des. 2011, 17:2421-2427.
24. Suh D.H., Kim M.K., No J.H., et al. Metabolic approaches to overcoming chemoresistance in ovarian cancer. Ann. N. Y. Acad. Sci. 2011, 1229:53-60.
25. Arora S., Bisanz K.M., Peralta L.A., et al. RNAi screening of the kinome identifies modulators of cisplatin response in ovarian cancer cells. Gynecol. Oncol. 2010, 118:220-227.
26. Kang J., D'Andrea A.D., Kozono D. A DNA repair pathway-focused score for prediction of outcomes in ovarian cancer treated with platinum-based chemotherapy. J. Natl. Cancer Inst. 2012, 104:670-681.
27. Lo C.W., Chen M.W., Hsiao M., et al. Malignant ascites in ovarian cancer IL-6 trans-signaling in formation and progression of malignant ascites in ovarian cancer. Cancer Res. 2011, 71:424-434.
28. Guo Y., Nemeth J., O'Brien C., et al. Effects of siltuximab on the IL-6-induced signaling pathway in ovarian cancer. Clin. Cancer Res. 2010, 16:5759-5769.
29. Grivennikov S., Karin E., Terzic J., et al. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 2009, 15:103-113.
30. Asschert J.G., Vellenga E., Ruiters M.H., et al. Regulation of spontaneous and TNF/IFN-induced IL-6 expression in two human ovarian-carcinoma cell lines. Int. J. Cancer 1999, 82:244-249.
31. Montopoli M., Bellanda M., Lonardoni F., et al. "Metabolic reprogramming" in ovarian cancer cells resistant to cisplatin. Curr. Cancer Drug Targets 2011, 11:226-235.
32. Liu J., Xu X., Feng X., et al. Adenovirus-mediated delivery of bFGF small interfering RNA reduces STAT3 phosphorylation and induces the depolarization of mitochondria and apoptosis in glioma cells U251. J. Exp. Clin. Cancer Res. 2011, 30:80.
33. Wegrzyn J., Potla R., Chwae Y.J., et al. Function of mitochondrial Stat3 in cellular respiration. Science 2009, 323:793-797.